Novo Nordisk faces US Senate inquiry over weight loss drug prices
王俊杰2017
发表于 2024-9-23 14:21:44
213
0
0
According to the website of the United States Senate, the Senate will hold a hearing on September 24 local time to examine whether Novo Nordisk provides overpriced smeglutide products Ozempic and Wegovy for patients with diabetes and obesity.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Tianfeng International analyst Guo Mingchi: Apple's affordable Vision Pro production has been postponed until after 2027
- Nvidia agrees to TSMC raise 3nm and CoWoS prices
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Bitcoin price once hit a new historical high of $95000
- 1 Bitcoin ≥ 100000 USD! Reviewing the Path of Bitcoin Price Soaring
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%
